In recent years, the therapeutic landscape for hematological malignancies has undergone a profound transformation, driven by ...

Genetic engineering technologies allow for the creation of custom-made cells that can have transformative effects on human health. This is best exemplified by chimeric antigen receptor (CAR ...

Researchers have developed an innovative dual-receptor T-cell therapy that promises safer and more effective cancer ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

A recently developed cancer treatment called chimeric antigen receptor T-cell therapy (CAR T-cell therapy, for short) offers hope to people whose diffuse large B-cell lymphoma (DLBCL) has proved ...

In recent years, CAR-T cell immunotherapy (using chimeric antigen receptors) has revolutionized the fight against cancer. In combination with other tools (chemotherapy, radiotherapy), this new ...

Cancer patients living in southern Utah and nearby states now have a facility offering a highly specialized treatment much closer to home.

Using a multipronged strategy, Celyad is driving the development of next-generation chimeric antigen receptor-T cell-based therapies to treat cancer. Lead programs include both autologous and ...

(1) A chimeric antigen receptor (CAR) is a modular, synthetic receptor that endows T cells with different targeting abilities. Several emerging engineering approaches aim to improve the safety, ...

In the last decade, a new immunotherapy tool has entered the clinic. T cells engineered to express chimeric antigen receptors, known as CAR T cells, have been shown to help patients with blood cancer.

If you or a loved one has diffuse large B-cell lymphoma (DLBCL) that is no longer responding to treatment or came back after treatment, chimeric antigen receptor (CAR) T-cell therapy may be an option.